Arvinas Inc (ARVN)

May 31, 2025, 8:06 AM EDT - 2 days ago

Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression

PFE

May 31, 2025, 8:00 AM EDT - 2 days ago

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer

May 30, 2025, 7:00 AM EDT - 3 days ago

Arvinas to Present at Jefferies Global Healthcare Conference

May 16, 2025, 10:00 AM EDT - 17 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Shareholders to Inquire about Securities Investigation

May 15, 2025, 10:00 AM EDT - 18 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Arvinas, Inc. (ARVN) And Encourages Shareholders to Connect

May 14, 2025, 10:00 AM EDT - 19 days ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Shareholders to Reach Out

May 13, 2025, 10:00 AM EDT - 20 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arvinas, Inc. (ARVN) and Encourages Shareholders to Learn More About the Investigation

May 12, 2025, 10:00 AM EDT - 21 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arvinas, Inc. (ARVN) and Encourages Investors to Learn More About the Investigation

May 11, 2025, 10:00 AM EDT - 22 days ago

Arvinas, Inc. (ARVN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 9, 2025, 10:00 AM EDT - 24 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Arvinas, Inc. (ARVN) And Encourages Investors to Connect

May 8, 2025, 10:00 AM EDT - 25 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Stockholders to Inquire about Securities Investigation

May 7, 2025, 10:00 AM EDT - 26 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Investors to Inquire about Securities Investigation

May 6, 2025, 10:00 AM EDT - 27 days ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Investors to Reach Out

May 5, 2025, 10:00 AM EDT - 4 weeks ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Stockholders to Reach Out

May 4, 2025, 4:17 PM EDT - 4 weeks ago

Arvinas: Yet Another Biotech Trading Below Net Cash, But It's Only A Mild Bull Case

May 4, 2025, 10:00 AM EDT - 4 weeks ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Arvinas, Inc. (ARVN) And Encourages Stockholders to Connect

May 2, 2025, 5:00 PM EDT - 4 weeks ago

Arvinas, Inc. (ARVN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

May 2, 2025, 8:15 AM EDT - 4 weeks ago

Arvinas, Inc. (ARVN) Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm's Investigation

May 1, 2025, 9:40 PM EDT - 4 weeks ago

Arvinas, Inc. (ARVN) Q1 2025 Earnings Call Transcript

May 1, 2025, 7:00 AM EDT - 4 weeks ago

Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apr 28, 2025, 7:00 AM EDT - 5 weeks ago

Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

Apr 28, 2025, 6:45 AM EDT - 5 weeks ago

Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting

Apr 23, 2025, 10:44 AM EDT - 5 weeks ago

Arvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 21, 2025, 7:00 AM EDT - 6 weeks ago

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research® (AACR) Annual Meeting

Apr 4, 2025, 3:38 PM EDT - 2 months ago

Arvinas Potential Parkinson's Treatment Shows Positive Data In Human Study

Apr 4, 2025, 7:00 AM EDT - 2 months ago

Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation

Mar 27, 2025, 7:00 AM EDT - 2 months ago

Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer's & Parkinson's Diseases

Mar 26, 2025, 7:06 AM EDT - 2 months ago

Top 3 Health Care Stocks That Are Set To Fly This Month

IOVA SLP

Mar 11, 2025, 12:30 PM EDT - 2 months ago

Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial

PFE

Mar 11, 2025, 6:58 AM EDT - 2 months ago

Arvinas-Pfizer's breast cancer treatment meets main goal in late-stage study

PFE

Mar 11, 2025, 6:45 AM EDT - 2 months ago

Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial

PFE

Mar 4, 2025, 4:05 PM EST - 3 months ago

Arvinas to Participate in Upcoming Investor Conferences

Feb 12, 2025, 12:04 PM EST - 3 months ago

These Analysts Revise Their Forecasts On Arvinas After Q4 Results